Unleashing TNF cytotoxicity to enhance cancer immunotherapy.

Trends Immunol

Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia; Department of Immunology and Pathology, Monash University, Melbourne, VIC 3004, Australia. Electronic address:

Published: December 2021

Tumor necrosis factor (TNF) is a proinflammatory cytokine that is produced and secreted by cytotoxic lymphocytes upon tumor target recognition. Depending on the context, TNF can mediate either pro-survival or pro-death signals. The potential cytotoxicity of T cell-produced TNF, particularly in the context of T cell-directed immunotherapies, has been largely overlooked. However, a spate of recent studies investigating tumor immune evasion through the application of CRISPR-based gene-editing screens have highlighted TNF-mediated killing as an important component of the mammalian T cell antitumor repertoire. In the context of the current understanding of the role of TNF in antitumor immunity, we discuss these studies and touch on their therapeutic implications. Collectively, we provide an enticing prospect to augment immunotherapy responses through TNF cytotoxicity.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.it.2021.10.003DOI Listing

Publication Analysis

Top Keywords

tnf cytotoxicity
8
tnf
5
unleashing tnf
4
cytotoxicity enhance
4
enhance cancer
4
cancer immunotherapy
4
immunotherapy tumor
4
tumor necrosis
4
necrosis factor
4
factor tnf
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!